Bodyweight gain with atypical antipsychotics. A comparative review.
about
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistanceTreatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trialFlupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.Current options in the management of olanzapine-associated weight gain.Screening the receptorome.Genetics of antipsychotic treatment emergent weight gain in schizophrenia.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.Clozapine: Current perspective.Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.Weight gain, obesity, and psychotropic prescribing.Weight gain and new onset diabetes associated with olanzapine and risperidone.Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009.Management of atypical antipsychotic drug-induced weight gain: focus on metformin.Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus.Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapyAssociation of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study).The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans.Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.New targets in the treatment of anorexia nervosa.A review of clozapine safety.Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Current schizophrenia drugs: efficacy and side effects.Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review.Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesityThe association between weight change and symptom reduction in the CATIE schizophrenia trial.Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapineBody Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite LevelsIncreased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications.Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.Overweight and obesity in youth with developmental disabilities: a call to action.Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.The impact of weight gain associated with atypical antipsychotic use in schizophrenia.Atypical antipsychotics in the therapy of bipolar disorders: efficacy and safety.
P2860
Q22241393-ADD9990B-8333-4FC5-98EE-1EB8BEBA13F0Q27323282-752BA0CA-B166-4CBF-8C9B-1BA74A120FE6Q30489980-F5FBFAB8-5A8B-4DD6-9ECD-41B5558C03DEQ30654033-1A883D6D-26A9-4F9B-962E-B2662288B983Q31138909-C13CFA62-B2FE-494A-9108-592F6E164880Q33247259-CBD05754-324E-41D0-A34D-93234410931CQ33257886-70506C82-4C66-4F14-9713-EED78FDC5C0BQ33964839-B0B9908E-636A-4E9E-BB7C-9531C91C070DQ34006864-A68142DD-7D53-4456-AD9F-53536A5C5F2BQ34021447-AEF614CE-E0AE-451A-ACDE-4706675F89B4Q34543946-D5C26454-7719-4426-8CB7-6A966E69747FQ34557537-5A284F35-361D-4716-AD2F-7F5C0B3F9189Q34733828-71E1A234-A5BC-4A5B-AE7F-86F500DE3EFFQ34770565-02531AE9-3EEC-440E-8DC2-BD1E36BF5D86Q34983478-ADD45833-E8F1-48C5-B275-7E41E5D9AC84Q34991293-1F3F5895-F66F-465D-ABEA-02DB68EE2241Q35017231-DD9BC9B0-5B57-4719-A134-4FE4DBEE6139Q35082380-170F648E-8749-4182-9460-65FBC64CF3B9Q35153031-21F74458-00AB-4063-89AD-BFEEF6EEA9AFQ35460642-4992DB3B-AC53-45B1-94AF-FD3BCC389350Q35752734-85EEDDD1-8B04-4056-9013-CD79015A56B7Q35945454-5C6A97CC-93DD-48E0-926E-6C6D1F9451C5Q36061639-48F8D1C7-1A6B-44FC-829F-3D542799B534Q36066305-A1CA190C-344A-4337-AE90-64D402571145Q36191044-F365D02C-A450-4EE5-90D8-19B7F82C56D6Q36474147-320CC675-E8F4-4455-BB03-41043C4C72F5Q36488206-8A66A6FA-53BB-493D-9CDA-DC0E1DBC3129Q36893286-65CACEC4-E19B-4593-BD96-7573838F1C73Q37047473-9D09B6CB-9447-431A-A303-4C1F11CFF5BFQ37189415-C91C9133-1B51-481C-92DE-026A90CBB754Q37212106-85EA3E73-C9FD-49D8-88E9-967B8D1DA439Q37233562-4EB2611A-E61D-43B3-9A18-E033449EBEE8Q37239636-F6F89AED-94D4-471A-BBFA-5FA5C53D8C6BQ37644575-7EAC106E-B5FD-4371-A2F3-1944EF3D37CBQ37958894-EFF23F62-3AF1-443C-AE49-A612E9B9CA2DQ38135881-EE457107-154C-47C2-8F45-430F56B8C202Q38163397-A48BF284-FD58-4359-8494-8B2BA0B45CD1Q38708352-A230C963-0273-40DF-BFB7-FE00D6740541Q38777526-9692610B-59FB-4BA6-9C46-6F7E0961EFFAQ40644004-1C3D24B2-D7C0-4B2E-AECC-B18F696CFB0E
P2860
Bodyweight gain with atypical antipsychotics. A comparative review.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Bodyweight gain with atypical antipsychotics. A comparative review.
@ast
Bodyweight gain with atypical antipsychotics. A comparative review.
@en
type
label
Bodyweight gain with atypical antipsychotics. A comparative review.
@ast
Bodyweight gain with atypical antipsychotics. A comparative review.
@en
prefLabel
Bodyweight gain with atypical antipsychotics. A comparative review.
@ast
Bodyweight gain with atypical antipsychotics. A comparative review.
@en
P1433
P1476
Bodyweight gain with atypical antipsychotics. A comparative review.
@en
P2093
T Wetterling
P356
10.2165/00002018-200124010-00005
P577
2001-01-01T00:00:00Z
P6179
1024666974